CTC Dx Firm Biocept Goes Public at $10 per Share | GenomeWeb

NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

In afternoon trading, the company's shares, which trade under ticker symbol "BIOC" on the Nasdaq, were down 6 percent at $9.39.

The San Diego-based oncology diagnostics firm offered 1.9 million shares of its common stock as part of its IPO, which is expected to bring in $19 million in gross proceeds. The offering is expected to close on Feb. 10.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.